Please join us on Thursday, January 30, 2020, for a webinar during which we will discuss California’s new reverse payment law—AB-824, Preserving Access to Affordable Drugs—and what it means for settlements of patent litigation involving generic pharmaceuticals and biosimilars across the nation. The webinar will feature Mark A. Ford, a partner in WilmerHale’s Antitrust and Competition Group, who focuses on issues at the antitrust-IP intersection.
During the webinar, we will:
- break down the new law, which went into effect January 1, and highlight how the California law’s treatment of so-called reverse payment settlements differs from the treatment of those settlements under federal antitrust law in the wake of Fed. Trade Comm’n v. Actavis, 570 U.S. 136 (2013);
- analyze the practical implications the California law has for litigation cost avoidance payments, which have been a common feature of Hatch-Waxman settlements, even after Actavis; and
- provide an update on a pending constitutional challenge to California’s law, which is currently on appeal to the Ninth Circuit.
*CLE credit is not available for those who watch webinar recordings.